Form 4: Denali Director Steve Krognes Receives Equity Grants

Director Steve E. Krognes was granted 6,408 restricted stock units and 19,226 stock options as part of annual board compensation.

Summary

• Steve E. Krognes, a member of the Board of Directors, received two separate equity awards on June 3, 2026.
• The first award consists of 6,408 Restricted Stock Units (RSUs), which represent a contingent right to receive shares of common stock.
• The second award consists of 19,226 stock options with an exercise price of $19.66 per share.
• Both the RSUs and the stock options are scheduled to vest 100% on the earlier of June 3, 2027, or the day before the next annual meeting of stockholders.
• Following these transactions, Krognes directly owns 38,202 shares and indirectly holds 781,797 shares through a revocable trust.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it confirms the continued engagement of an experienced director and maintains high levels of insider ownership.

Positives

• The director maintains a substantial indirect stake of 781,797 shares, signaling long-term confidence in the company.
• Equity-based compensation aligns the interests of board members with those of the shareholders.
• The exercise price for the new options is set at $19.66, providing an incentive for the director to drive share price appreciation.

Negatives

• The grants represent potential future dilution of existing shares, totaling 25,634 new shares or options.

Risks

• The stock options will expire worthless on June 3, 2036, if the market price does not exceed the $19.66 exercise price.
• Equity awards are subject to forfeiture if the reporting person ceases to provide service to the issuer before the one-year vesting cliff.

Future Outlook

The reporting person's equity awards are tied to a one-year service period, suggesting a commitment to board service through at least mid-2027.

Management Comments

• No specific management commentary was provided in this regulatory filing.

Industry Context

StockSavvy.ai notes that Denali Therapeutics, like many clinical-stage biotechnology firms, utilizes heavy equity-based compensation for directors to preserve cash for research and development while ensuring board alignment with long-term clinical milestones.

Comparison to Industry Standards

• The grant size is consistent with mid-cap biotechnology peers such as Ultragenyx Pharmaceutical and Sage Therapeutics.
• A one-year cliff vesting schedule for director equity is the standard practice for companies listed on the NASDAQ.
• The use of a mix of RSUs and options is a common balanced approach to director compensation in the healthcare sector.

Corporate Governance

Related Party Transactions

• The reporting person holds 781,797 shares through The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016.

Stakeholder Impact

• Shareholders may face minor dilution from the eventual issuance of up to 25,634 shares.
• The board of directors maintains stability with the continued service of Steve Krognes.

Next Steps

• Vesting of 6,408 RSUs on or before June 3, 2027.
• Vesting of 19,226 stock options on or before June 3, 2027.

Key Dates

Recommendation

The filing reflects routine insider compensation activity and does not indicate a change in company fundamentals or a significant shift in insider sentiment beyond standard annual grants.

Keywords

Denali Therapeutics, DNLI, Insider Trading, Form 4, Steve Krognes, Stock Options, Restricted Stock Units, Director Compensation, Biotechnology